EMA/202333/2013

European Medicines Agency decision

P/0119/2013

of 3 May 2013

on the agreement of a paediatric investigation plan for autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA (EMEA-001244-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0119/2013

of 3 May 2013

on the agreement of a paediatric investigation plan for autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA (EMEA-001244-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by bluebird bio France on 9 January 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 March 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA, suspension for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to bluebird bio France, Hopital Saint Louis, Centre Hayem, 1 avenue Claude Vellefaux, 75010 – Paris, France.

Done at London, 3 May 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/819984/2012 Corr

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-001244-PIP01-11

Scope of the application

Active substance(s):

Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA

Condition(s):

Treatment of adrenoleukodystrophy

Pharmaceutical form(s):

Suspension for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

bluebird bio France

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, bluebird bio France submitted for agreement to the European Medicines Agency on 9 January 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 February 2012.

Supplementary information was provided by the applicant on 17 December 2012. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a deferral and a waiver.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 15 March 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of adrenoleukodystrophy

2.1.1. Indication(s) targeted by the PIP

Treatment of adrenoleukodystrophy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Suspension for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality		Not applicable.
Non-clinical	4	**Measure 1) NC-12-001** In vitro pharmacology, Evaluation of adrenoleukodystrophy protein (ALDP) expression level in primary ALDP negative fibroblast **Measure 2) NC-12-005** In vitro pharmacology, Demonstration of biochemical function of expressed adrenoleukodystrophy protein (ALDP) after Lenti-D transduction by measuring very long chain fatty acids (VLCFA) reduction in the transduced ALD- CD34+ cells. **Measure 3) NC-12-006** In vitro pharmacology, Demonstration of efficient transduction of long term repopulating cells derived from Lenti-D transduced normal CD34+ cells and ALD- CD34+ cells using Long Term Culture **Measure 4) Biodistribution** Investigation of biodistribution of cells derived from Lenti-D transduced cells into the brain

Clinical	1	**Measure 5) ALD-102** Open label, single dose study in boys with childhood cerebral adrenoleukodystrophy (CCALD) to demonstrate the activity and safety of Lenti-D modified autologous haematopoietic stem cells in the treatment of CCALD

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2018
Deferral for one or more studies contained in the paediatric investigation plan:	No